Stavely Minerals Ltd (ASX: SVY) identitii Ltd (ASX: ID8) and Bionomics Ltd (ASX: BNO) Explode On Groundbreaking Updates

Sector Reports > Latest News > ASX > Stavely Minerals Ltd (ASX: SVY) identitii Ltd (ASX: ID8) and Bionomics Ltd (ASX: BNO) Explode On Groundbreaking Updates

Sector Reports are pleased to announce our coverage on the below stocks.

For daily updates, news, trade ideas and complimentary research reports please insert your email in the box below and get instant access to our latest research reports, which include Cannabis, AI, Gold and more.

Stavely Minerals Ltd (ASX: SVY), identitii Ltd (ASX: ID8) and Bionomics Ltd (ASX: BNO) were big movers on huge volume; as investors reacted to a series of positive news that affirms long-term prospects.

Enter Your Email for Instant Access to the Best Free ASX Research on the Markets

Stavely Explodes On Positive Exploration Results.

Stavely Minerals exploded in the market after announcing outstanding shallow high-grade copper-gold discovery as part of its copper-gold project in Victoria. The stock was up by more than 200% as investors reacted to the news that affirms prospects in the Victoria copper-gold project.

The exceptional results come from a diamond hole SMD050 that targeted high-grade structural controlled mineralization within the ultramafic Contact fault.

In a press release, the company notes that the drill hole intersected a zone of 14.6 meters made up of massive sulphides as well as chalcopyrite bornite and chalcocite at between 79 m and 93.6m of the drill depth. The assay received include 5.88% copper at 32 meters, 1.00g/t gold and 58g/t at 62m.

“Additional mineralized structures are thought to exist without surface expression but are expected to provide a strong conductive response to a ground EM survey which is being designed, also as a priority,” said Stavely Minerals’ Executive Chairman, Chris Cairns.

Identitii To Test Open Banking Ecosystem

Identitii Limited was also a big mover rallying by more than 40% on the confirmation it is one of only ten companies selected to test the Consumer Data Right ecosystem by the Australian Competition and Consumer Commission.

The selection positions the company to be among the first company eligible for accreditation under the incoming CDR rules. Selection, in this case, will allow the company to be among the first allowed to access open banking data in Australia. The company joins the likes of Intuit and Neobank that are also in the running for the accreditation.

Access to open banking data should give rise to new opportunities, especially for identitii Overlay+solution. For starters, the company will be able to leverage rich information that most companies have used over the years to unlock value from corporate balance sheets.

Bionomics PTSD Treatment Prospects

Bionomics Limited was also up by more than 40% after announcing positive trial results as part of its ongoing pharmacokinetic study of its lead candidate drug BNC210. Study results have already shown that the lead candidate drug has the potential to achieve blood levels needed to meet primary endpoints, in the treating of Post-Traumatic Stress Disorder.

The positive trial results come hot on the heels of the biopharmaceutical company attending a Type C meeting with the Food and Drug Administration. The meeting sought to set the framework for the development of BNC210 as a potential treatment of PTSD.

The company is also pushing for a Fast Track designation of the lead candidate drug. A Fast Track designation for BNC210 would help expedite its regulatory review in the wake of recent trial results that have shown it has the potential to treat serious conditions and address an unmet medical need as well.


Enter Your Email for Instant Access to the Best Free ASX Research on the Markets



This website is a service of Profectus Solutions Pty. Ltd. an investor relations group and media firm. The website or article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Profectus is not responsible for material posted on this website and does not guarantee the content, accuracy, or use of the content in this site. No advice or information, whether oral or written, obtained by you from Profectus Solutions or through or from the service shall create any warranty not expressly stated.

Profectus Solutions do not offer financial advice based upon your personal financial situation or goals, and we shall NOT be held liable for any investment or trading losses you may incur by using the opinions expressed in our publications, market updates, news alerts and corporate profiles. Profectus does not in any way endorse or recommend individuals, products or services that may be discussed on this site. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional licensed financial planner and adviser. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

Conflict of interest

Directors, staff or third parties of Profectus may at times own shares of companies that are profiled within our network. We as part of our business model actively seek to do business with listed ASX or other companies.

We have NOT been compensated for the production of this webpage.

Leave a Reply

Your email address will not be published.